{rfName}
Lo

Indexed in

License and use

Citations

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Gonzalez Baeza, AliciaAuthor

Share

Publications
>
Article

Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: An analysis of a multicentre cohort at 96 weeks

Publicated to:Journal of Antimicrobial Chemotherapy. 2025; 80 (3): 682-691 - 2025-03-01 80(3), DOI: 10.1093/jac/dkae456

Authors: Suárez-García I; Alejos B; Moreno C; Martín Torres J; Masiá M; García-Fraile LJ; Riera M; Dalmau D; Rodríguez-Rosado R; Muga R; Moreno S; Jarrín I; Luisa Navarro M; Isabel González M; Garcia F; Poveda E; Iribarren JA; Gutiarrez F; Rubio R; Vidal F; Berenguer J; González J; Ángeles Muñoz-Fernández M; Jarrín I; Rava M; Izquierdo R; Marco C; Gómez-García T; Juárez R; Portilla J; Portilla I; Merino E; García G; Agea I; Sánchez-Payá J; Rodríguez JC; Giner L; Reus S; Boix V; Torrus D; Parez V; Portilla J; Pinargote H; Alemán MR; Lirola López A; García D; Díaz-Flores F; Pelazas R; Hernández MI; Romero L; Bethencourt A; Rodríguez D; Asensi V; Rivas-Carmenado ME; Magadan RC; Díaz-Arias J; Pulido F; Bisbal O; Asunción Hernando M; Rial D; De Lagarde M; Pinto A; Bermejo L; Santacreu M; Navarro R; Torres JM; Iribarren JA; Josa Aramburu M; Camino X; Goenaga MÁ; Jesús Bustinduy M; Azkune H; Ibarguren M; Kortajarena X; Álvarez-Rodriguez I; Gil L; Carmona-Torre F; Carlos AB; Sanz ML; Robledano C; Padilla S; Adsuar A; Pascual R; Fernández M; Galiana A; García JA; Barber X; Abellán JG; Telenti G; Guillan L; Botella Á; Mascarell P; Carvajal M; De La Rica A; Ding C; García-Sánchez L; Ena N; López L; Vallejo J; Gonzalo-Jimanez N

Affiliations

Abstract

Objectives: To evaluate the long-term effectiveness, persistence and tolerability of dolutegravir (DTG)/lamivudine (3TC), compared with the most frequently prescribed first-line treatment regimens, among antiretroviral-naive people with HIV from CoRIS, a multicentre cohort in Spain, in 2018-23. Methods: We used multivariable regression models to compare viral suppression (VS) (HIV RNA viral load <50 copies/mL), change in CD4 cell counts, persistence and treatment discontinuations due to adverse events (AEs), at 96 (±24) weeks after treatment initiation. Results: Of 2359 participants, DTG/3TC was prescribed in 472 (20.0%), bictegravir/tenofovir alafenamide (TAF)/ emtricitabine (FTC) in 1134 (48.1%), DTG + tenofovir disoproxil fumarate/FTC in 300 (12.7%), DTG/abacavir/3TC in 273 (11.6%) and darunavir/cobicistat/TAF/FTC in 180 (7.6%). At 96 weeks from treatment initiation, 94.0% of participants initiating with DTG/3TC achieved VS, and the mean increase in CD4 cell counts was 295.5 cells/μL (95% CI: 269.9-321.1). During the first 96 weeks after DTG/3TC initiation, 9.8% and 1.3% discontinued their initial regimen, overall and due to AEs, respectively. In multivariable analyses, we did not find significant differences in VS or increase in CD4 cell counts among participants initiating with DTG/3TC compared with other regimens. Initiating ART with a regimen other than DTG/3TC was associated with a higher risk of treatment discontinuation, overall and due to AEs. Conclusions: Among treatment-naive people with HIV from this large multicentre cohort, DTG/3TC had similar effectiveness and better persistence and tolerability than those of the most frequently prescribed first-line regimens at 96 weeks.

Keywords

Quality index

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-27:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 11.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 11 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 9.58.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Ensure healthy lives and promote well-being for all at all ages, with a probability of 85% according to the mBERT algorithm developed by Aurora University.